

<b>Notice of References Cited</b>	Application/Control No. 10/700,922	Applicant(s)/Patent Under Reexamination BERGMANN ET AL.	
	Examiner Gregory S. Emch	Art Unit 1649	Page 1 of 3

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Purves, Dale, et al (Eds.), Neuroscience, 2001, Sinauer Associates, Inc., 2nd Edition, pp.75, 367, 400, 403, 554, 555, 640, 641, 678 and 679.
	V	Bridler et al. Atypical antipsychotics in the treatment of schizophrenia. Swiss Med Wkly. 2003 Feb 8;133(5-6):63-76.
	W	Branas et al. Treatments for fatigue in multiple sclerosis: a rapid and systematic review: executive summary, Health Technol Assess, 2000; 4(27): pp.1-4.
	X	Oksenberg. Selective targeting of the immune response in autoimmune demyelination. West J Med. 1994 Sep; 161(3): 255-9.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

<b>Notice of References Cited</b>	Application/Control No. 10/700,922	Applicant(s)/Patent Under Reexamination BERGMANN ET AL.	
	Examiner Gregory S. Emch	Art Unit 1649	Page 2 of 3

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
*	U	Kienzl et al. A broader horizon of Alzheimer pathogenesis: ALZAS--an early serum biomarker? J Neural Transm Suppl. 2002;(62):87-95.
	V	Perez et al. The beta-amyloid precursor protein of Alzheimer's disease enhances neuron viability and modulates neuronal polarity. J Neurosci. 1997 Dec 15;17(24):9407-14.
	W	Liu et al. Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13266-71.
	X	Casadesus et al. The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease. Drugs in R&D, 2006; 7(3):187-193.

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

<b>Notice of References Cited</b>	Application/Control No. 10/700,922	Applicant(s)/Patent Under Reexamination BERGMANN ET AL.	
	Examiner Gregory S. Emch	Art Unit 1649	Page 3 of 3

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	de Lustig et al. Peripheral markers and diagnostic criteria in Alzheimer's disease: critical evaluations. Rev Neurosci. 1994 Jul-Sep;5(3):213-24.
	V	
	W	
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.